Aller directement au menu principal Aller directement au contenu principal Aller au pied de page
Cortica

Cortica explique-moi

Vol. 2 No. 2 (2023): OPEN SCIENCE : Accès aux savoirs scientifiques auprès des professionnels de santé et contribuer à la littératie scientifique citoyenne

Psychedelics in therapy

  • Thomas Cardoso de Oliveira
  • Tommaso Portesan
  • Yelena Caloz
DOI
https://doi.org/10.26034/cortica.2023.4187
Soumise
August 28, 2023
Publié-e
2023-09-19

Résumé

Psychedelics in therapy

Références

  1. Bell, R. F., Eccleston, C., & Kalso, E. A. (2017). Ketamine as an adjuvant to opioids for cancer pain. The Cochrane Database of Systematic Reviews, 2017(6), CD003351. https://doi.org/10.1002/14651858.CD003351.pub3
  2. Carhart-Harris, R. L., & Goodwin, G. M. (2017). The Therapeutic Potential of Psychedelic Drugs : Past, Present, and Future. Neuropsychopharmacology, 42(11), 2105‑2113. https://doi.org/10.1038/npp.2017.84
  3. Coyle, C. M., & Laws, K. R. (2015). The use of ketamine as an antidepressant : A systematic review and meta-analysis. Human Psychopharmacology: Clinical and Experimental, 30(3), 152‑163. https://doi.org/10.1002/hup.2475
  4. Goodman, N. (2002). The Serotonergic System and Mysticism : Could LSD and the Nondrug-Induced Mystical Experience Share Common Neural Mechanisms? Journal of Psychoactive Drugs, 34(3), 263‑272. https://doi.org/10.1080/02791072.2002.10399962
  5. Grady, S. E., Marsh, T. A., Tenhouse, A., & Klein, K. (2017). Ketamine for the treatment of major depressive disorder and bipolar depression : A review of the literature. Mental Health Clinician, 7(1), 16‑23. https://doi.org/10.9740/mhc.2017.01.016
  6. Gregorio, D. D., Aguilar-Valles, A., Preller, K. H., Heifets, B. D., Hibicke, M., Mitchell, J., & Gobbi, G. (2021). Hallucinogens in Mental Health : Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine. Journal of Neuroscience, 41(5), 891‑900. https://doi.org/10.1523/JNEUROSCI.1659-20.2020
  7. Hake, H. S., Davis, J. K. P., Wood, R. R., Tanner, M. K., Loetz, E. C., Sanchez, A., Ostrovskyy, M., Oleson, E. B., Grigsby, J., Doblin, R., & Greenwood, B. N. (2019). 3,4-methylenedioxymethamphetamine (MDMA) impairs the extinction and reconsolidation of fear memory in rats. Physiology & Behavior, 199, 343‑350. https://doi.org/10.1016/j.physbeh.2018.12.007
  8. Johnson, M. W., & Griffiths, R. R. (2017). Potential Therapeutic Effects of Psilocybin. Neurotherapeutics, 14(3), 734‑740. https://doi.org/10.1007/s13311-017-0542-y
  9. Kim, K., Che, T., Panova, O., DiBerto, J. F., Lyu, J., Krumm, B. E., Wacker, D., Robertson, M. J., Seven, A. B., Nichols, D. E., Shoichet, B. K., Skiniotis, G., & Roth, B. L. (2020). Structure of a Hallucinogen-Activated Gq-Coupled 5-HT2A Serotonin Receptor. Cell, 182(6), 1574-1588.e19. https://doi.org/10.1016/j.cell.2020.08.024
  10. Lewis-Healey, E., Laukkonen, R., & van Elk, M. (20220526). Future directions for clinical psilocybin research : The relaxed symptom network. Psychology & Neuroscience, 15(3), 223. https://doi.org/10.1037/pne0000290
  11. Nichols, D. E. (2016). Psychedelics. Pharmacological Reviews, 68(2), 264‑355. https://doi.org/10.1124/pr.115.011478
  12. Orhurhu, V., Orhurhu, M. S., Bhatia, A., & Cohen, S. P. (2019). Ketamine Infusions for Chronic Pain : A Systematic Review and Meta-analysis of Randomized Controlled Trials. Anesthesia & Analgesia, 129(1), 241. https://doi.org/10.1213/ANE.0000000000004185
  13. Reiff, C. M., Richman, E. E., Nemeroff, C. B., Carpenter, L. L., Widge, A. S., Rodriguez, C. I., Kalin, N. H., & McDonald, W. M. (2020). Psychedelics and Psychedelic-Assisted Psychotherapy. American Journal of Psychiatry, 177(5), 391‑410. https://doi.org/10.1176/appi.ajp.2019.19010035
  14. Studerus, E., Vizeli, P., Harder, S., Ley, L., & Liechti, M. E. (2021). Prediction of MDMA response in healthy humans : A pooled analysis of placebo-controlled studies. Journal of Psychopharmacology (Oxford, England), 35(5), 556‑565. https://doi.org/10.1177/0269881121998322
  15. Vollenweider, F. X., & Kometer, M. (2010). The neurobiology of psychedelic drugs : Implications for the treatment of mood disorders. Nature Reviews Neuroscience, 11(9), Article 9. https://doi.org/10.1038/nrn2884